Biopharmas raising money in public or private financings, including: Cadrenal, Caribou, Galmed, Iovance.

Biopharmas raising money in public or private financings, including: 60 Degrees, Bicycle, Molecular Templates, Savara.

On the back of what Arthrosi Therapeutics LLC has called “remarkable efficacy and safety” data from a phase IIb trial of AR-882, a next-generation URAT1 inhibitor for treating gout, the company has padded its coffers with a $75 million series D round led by Guangrun Health Industry Co. Ltd. and backed by investors that include Reichstein Biotech Co. Ltd., a subsidiary of Arthrosi’s China joint venture partner Apichope Pharmaceuticals.

The U.K. medical research charity Lifearc has launched the first part of a £100 million (US$130 million) plan to promote translation of biomedical research into therapies for rare diseases, opening the program with a £2.5 million call for projects to repurpose existing drugs to treat the debilitating inherited skin disease epidermolysis bullosa (EB).

Biopharmas raising money in public or private financings, including: Arthrosi, Evelo, Painreform, Recce, Recursion, Stuart.

Kelun-Biotech Biopharmaceutical Co. Ltd. raised HK$1.36 billion (US$174 million) in an IPO in Hong Kong to support its push into the increasingly competitive antibody-drug conjugate (ADC) market in China.

Biopharmas raising money in public or private financings, including: Armata, Biorestorative, Iovance, Mallia, Mendus, Septerna.

Biopharmas raising money in public or private financings, including: Apogee, Evelo, Intensity, Sagimet.

Biopharmas raising money in public or private financings, including: Abeona, Bausch Health, IGC, Truebinding.